Utilisateur:JackBortone/Research/Notebook/Varenicline

De Open Neurosecurity Research Portal
Aller à la navigation Aller à la recherche

Title

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665036/

Important: "Use of varenicline while trying to quit smoking reduces and does not increase neuropsychiatric symptoms such as depressed mood and irritability measured on the MNWS in smokers without current psychiatric disorders."

https://pubmed.ncbi.nlm.nih.gov/23694782/

Test setup

  1. Start : apo-varenicline 1 x 0.5mg
  2. Test start date: 2024-03-02
  3. Test end date: 2024-03-05

Results

Results

1. Nicotine induced neuronal excitability can be blocked with nicotine partial-agonist (varenicline), thereby improving dopamine release and nicotine withdrawal. [1]

References

  1. Perez XA, Khroyan TV, McIntosh JM, Quik M. Pharmacol Res Perspect. 2015 Feb. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317236/

    [paper1]

  2. Author Name Press Name. Year https://researchspace.auckland.ac.nz/handle/2292/27522

    [paper2]

  3. Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials https://pubmed.ncbi.nlm.nih.gov/23694782/

    [paper3]
Récupérée de "https://www.open-neurosecurity.org/wiki/index.php?title=Utilisateur:JackBortone/Research/Notebook/Varenicline&oldid=3853"